Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection
- 1 October 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (14) , 1833-1844
- https://doi.org/10.1097/00002030-199814000-00015
Abstract
To evaluate the efficacy of combination protease and reverse transcriptase inhibitor therapy in correcting HIV-1-induced lymphocyte subset abnormalities in previously treated adults. A 48-week observational study of lymphocyte subsets in 12 participants in the Multicenter AIDS Cohort Study who were already taking at least one reverse transcriptase inhibitor and added a protease inhibitor to their treatment regimen. Comparison groups were HIV-seronegative homosexual men, HIV-seronegative heterosexual men, and homosexual HIV-1-infected men who were long-term nonprogressors. Three-color immunofluorescence and monoclonal antibodies were used to assess HIV-1-induced lymphocyte subset alterations related to immune deficiency and immune activation. Plasma HIV-1 RNA levels were monitored to assess suppression of viral replication. CD4+ cell counts significantly increased and lymphocyte activation measured as CD38 and HLA-DR expression on CD8+ T cells significantly decreased by 48 weeks. CD4+ cell values remained abnormal even in those who were fully suppressed. Some T-cell activation markers decreased to levels observed in long-term non-progressors. The increase in CD4+ T-cell numbers reached a plateau by week 24, but the increase in resting HLA-DR-CD38-T cells was sustained through week 48. Proportions of CD45RA+ CD62L-selectin+ and CD28+ CD4+ T-cell subsets and Fas expression were not abnormal at baseline compared with seronegative homosexual controls. The most significant impact of suppression of viral replication was reversal of T-cell activation. However, normalization of lymphocyte subset perturbations associated with chronic HIV-1 infection was not achieved after 1 year of treatment with current combination antiretroviral regimens. More profound viral suppression, therapy for longer than 1 year, or immunologic augmentation may be needed to fully reverse the abnormalities.Keywords
This publication has 36 references indexed in Scilit:
- Correlation of CD8 Lymphocyte Activation with Cellular Viremia and Plasma HIV RNA Levels in Asymptomatic Patients Infected by Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1996
- Expression of the fas antigen in patients infected with human immunodeficiency virusCytometry, 1995
- Expression of CD28 on CD8+ and CD4+ Lymphocytes During HIV InfectionScandinavian Journal of Immunology, 1994
- Expression of Costimulatory Molecule CD28 on T Cells in Human Immunodeficiency Virus Type 1 Infection: Functional and Clinical CorrelationsThe Journal of Infectious Diseases, 1994
- Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy".The Journal of Experimental Medicine, 1994
- The Impaired in Vitro Production of Interleukin-2 in HIV Infection Is Negatively Correlated to the Number of Circulating CD4+ DR+ T Cells and Is Reversed by Allowing T Cells to Rest in Culture: Arguments for in Vivo CD4+ T Cell ActivationClinical Immunology and Immunopathology, 1993
- Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45RO+ cells of the CD4 and CD8 lineagesAIDS, 1993
- Characterization of T Lymphocyte Subset Alterations by Flow Cytometry in HIV DiseaseAnnals of the New York Academy of Sciences, 1993
- T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort studyClinical Immunology and Immunopathology, 1989
- THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTSAmerican Journal of Epidemiology, 1987